Diabetes management with a care coordinator improves glucose control in African Americans and Hispanics.

BACKGROUND: The purpose of this study was to evaluate diabetes control, as measured by hemoglobin A1c (HbA1c) improvements among African American and Hispanic patients receiving conventional clinical treatment combined with a bilingual diabetes educator using culturally and linguistically appropriate educational materials. This study also sought to estimate the healthcare cost savings resulting from any A1c improvements and assess the cost-effectiveness of this approach. MATERIALS AND METHODS: This was a multistage, face-to-face observational study undertaken in Texas, United States and focused on 153 African American and Hispanic patients with poor blood glucose control (baseline A1c >8.0%). For two years, a bilingual care coordinator motivated patient behavior changes that could lead to improvements in glucose control. The primary evaluation measure was change in %HbA1c, with secondary measures being change in blood pressure (BP) and low-density lipoprotein (LDL). We also sought to gauge the program's potential cost-effectiveness. RESULTS: Within the study group, A1c levels decreased over the study period from a mean of 10.0% to 8.4%. The same group saw no statistically significant improvement (reduction) in blood concentrations of LDL. The African American subgroup had a small reduction in systolic BP while changes for non-White Hispanics were not statistically significant. The average A1c reduction realized in this observational study provided estimated cost savings that are nearly twice pilot expenditures. CONCLUSIONS: Combining standard diabetes care with a bilingual educational care coordinator results in significant reductions in mean A1c (-1.6% HbA1c) in patients with poorly controlled blood glucose and African American/non-White Hispanic heritage, an intervention that also was shown to be cost-effective. This may be an effective model for improving diabetes care in provider practices.

Eliminating medication copayments reduces disparities in cardiovascular care.

Substantial racial and ethnic disparities in cardiovascular care persist in the United States. For example, African Americans and Hispanics with cardiovascular disease are 10-40 percent less likely than whites to receive secondary prevention therapies, such as aspirin and beta-blockers. Lowering copayments for these therapies improves outcomes among all patients who have had a myocardial infarction, but the impact of lower copayments on health disparities is unknown. Using self-reported race and ethnicity for participants in the Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) trial, we found that rates of medication adherence were significantly lower and rates of adverse clinical outcomes were significantly higher for nonwhite patients than for white patients. Providing full drug coverage increased medication adherence in both groups. Among nonwhite patients, it also reduced the rates of major vascular events or revascularization by 35 percent and reduced total health care spending by 70 percent. Providing full coverage had no effect on clinical outcomes and costs for white patients. We conclude that lowering copayments for medications after myocardial infarctions may reduce racial and ethnic disparities for cardiovascular disease.

A comprehensive case management program to improve palliative care.

OBJECTIVE: The objective of this study was to evaluate the impact of comprehensive case management (CM) and expanded insurance benefits on use of hospice and acute health care services among enrollees in a national health plan. STUDY DESIGN: Retrospective cohort design with three intervention groups, each matched to a historical control group. METHODS: Intervention groups were health plan enrollees who died after 2004: 3491 commercial enrollees with CM; 387 commercial enrollees with CM and expanded hospice benefits; and 447 Medicare enrollees with CM. Control groups consisted of enrollees who died in 2004 prior to the start of the palliative care CM program. The main outcomes measured were the proportion using hospice, mean number of hospice days, and number of inpatient days measured through medical claims. RESULTS: Hospice use increased for all groups receiving CM compared to the respective control groups: from 30.8% to 71.7% (p < 0.0001) for commercial members with CM and from 27.9% to 69.8% (p < 0.0001) for Commercial members with CM and enhanced hospice benefits. Mean hospice days increased from 15.9 to 28.6 days (p < .0001) and from 21.4 to 36.7 days (p < 0.0001) for these groups, respectively. Inpatient stays were lower for all groups receiving CM services compared to their respective control groups. CONCLUSIONS: Comprehensive health plan CM and more liberal hospice benefit design may help to break down barriers to hospice use; benefits might be liberalized within the context of such case management programs without adverse impact on total costs.